IIIb期心脏AL淀粉样变性可发生早期心脏反应且与生存期延长相关
本研究评估249例新诊断IIIb期心脏AL淀粉样变性患者早期心脏反应及其深度对结局的影响。中位随访52个月,219例(84%)死亡,中位生存4.2个月。90天时21例(8%)达到心脏反应,心脏反应者中位生存54个月,且达到至少VGPR者中位生存62个月 vs 26个月(P=0.011)。
要点
- IIIb期心脏AL淀粉样变性患者90天心脏反应率仅8%,但心脏反应与生存期延长相关。
- 90天时达到至少VGPR且伴心脏反应者中位生存62个月 vs 26个月(P=0.011)。
- 基线受累/未受累游离轻链差>50 mg/L及骨髓浆细胞浸润>10%是90天心脏反应的负性预测因素。
核心结论
- IIIb期心脏AL淀粉样变性中早期心脏反应罕见但可能发生,并与生存期延长相关。
研究设计与样本
- 评估249例新诊断IIIb期心脏AL淀粉样变性患者早期心脏反应及其深度对结局的影响,血液学和心脏反应按意向治疗评估。
主要发现
- 中位随访52个月,219例(84%)死亡,中位生存4.2个月。
- 30天和90天血液学反应率分别为22%(至少VGPR 9%)和24%(至少VGPR 15%),早期血液学反应带来更好生存。
- 90天时21例(8%)达到心脏反应(其中心脏VGPR 12例,心脏PR 9例)。
- 90天地标分析中,心脏反应者中位生存54个月,达到至少VGPR者中心脏反应者中位生存62个月 vs 26个月(P=0.011)。
- 心脏VGPR者中位生存92个月 vs 心脏PR者24个月(P=0.027),无心脏反应者中位生存6个月。
关键数值与推荐
- 90天心脏反应定义为心脏VGPR或心脏PR,其中心脏VGPR 12例、心脏PR 9例。
- 30天血液学反应率22%(至少VGPR 9%),90天血液学反应率24%(至少VGPR 15%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with immunoglobulin light chain (AL) amyloidosis and stage IIIb cardiac involvement have a dismal outcome despite the introduction of novel treatments. However, a rapid hematologic response translates in better survival. We evaluated the impact of early cardiac response and its depth on outcome in 249 patients with newly diagnosed stage IIIb cardiac AL amyloidosis. Hematologic and cardiac responses were evaluated by intent to treat. After a median follow-up of 52 months, 219 (84%) patients died, and median survival was 4.2 months. The 30- and 90-day hematologic response rates were 22% (at least very good partial response [VGPR] in 9%) and 24% (at least VGPR in 15%), respectively. Early hematologic response resulted in better survival. At 90 days, 21 (8%) patients achieved a cardiac response (cardiac very good partial response [cardiac VGPR] in 12 cases and cardiac partial response [cardiac PR] in 9). At the 90-day landmark analysis, cardiac response resulted in longer survival (median, 54 months), also in those patients who have achieved at least VGPR (median, 62 vs 26 months, P = .011). Patients with cardiac VGPR had a longer survival than those with cardiac PR (median, 92 vs 24 months; P = .027), whereas patients without cardiac response had a poor survival (median, 6 months). A baseline difference of involved/uninvolved free light chains > 50 mg/L (odds ratio [OR], 0.21, P = .024) and a bone marrow plasma cell infiltrate > 10% (OR, 0.23, P = .040) were negative predictors of 90-day cardiac response. Early cardiac responses are rare but possible in stage IIIb AL amyloidosis and translate to longer survival.
引用
- Basset M, Milani P, Foli A, et al. Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival. Blood. 2022. PMID: 35772003. doi:10.1182/blood.2022016348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。